RGEN — REPLIGEN CORP
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 730272 ·
Last close
$162.18
Market Cap
$10.30B
52W High
$198.87
52W Low
$100.99
ADV30
1,243,725
Next earnings
2026-10-27
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 204,128,000 | 110,037,000 | 19,002,000 | 5,008,000 | 2,950,180,000 | 606,783,000 | 838,148,000 |
| Mar 2026 | 194,255,000 | 108,284,000 | 17,290,000 | 8,333,000 | 2,930,772,000 | 582,650,000 | 825,309,000 |
| Dec 2025 | 197,913,000 | 103,831,000 | 16,348,000 | 13,287,000 | 2,949,699,000 | 566,021,000 | 843,570,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$134,864,000
Investing CF
$-222,604,000
Financing CF
$-11,787,000
CapEx
$-24,711,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.21
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$469,589,000
Inventory
$186,604,000
Receivables
$157,710,000
ST Investments
$203,666,000
EBIT TTM
$74,300,000
Pretax Income TTM
$52,150,000
Interest Exp TTM
$22,150,000
Analysts
18
Yahoo Snapshot (yfinance, live)
Total Revenue
$805,609,984
EBITDA
$143,498,000
Free Cash Flow
$111,584,000
Enterprise Value
$9,860,477,952
Total Cash
$862,979,008
Total Debt
$692,241,024
Shares Out
63,490,365
Trailing EPS
$-0.21
Book Value
$36.90
ROE
-0.6%
ROA
1.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 738,256,000 | 41,560,000 | 48,894,000 | 2,949,699,000 | 843,570,000 | 2,106,129,000 | 117,417,000 |
| Dec 2024 | 634,439,000 | -31,923,000 | -25,514,000 | 2,829,666,000 | 856,948,000 | 1,972,718,000 | 175,394,000 |
| Dec 2023 | 632,362,000 | 17,134,000 | 35,596,000 | 2,831,185,000 | 866,340,000 | 1,964,845,000 | 113,918,000 |
| Dec 2022 | 801,536,000 | 195,941,000 | 185,959,000 | 2,531,600,000 | 620,900,000 | 1,910,700,000 | 172,083,000 |
TTM Snapshot
Revenues TTM
$785,101,000
NetIncome TTM
$41,539,000
OpCashFlow TTM
—
Assets (Latest)
$2,950,180,000
Forward EPS
$2.65
Max Pain — expiry 2026-12-18
max pain strike: $160.00 · spot: $172.67 · call oi: 1,889 · put oi: 4,060
Expected Move to 2026-12-18:
±$19.80
(11.47%) —
implied range
$152.87 –
$192.47
· ATM straddle on $175.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QGEN | QIAGEN N.V. | $10.27B | $49.75 | — |
| KYMR | Kymera Therapeutics, Inc. | $10.37B | $121.52 | — |
| HALO | HALOZYME THERAPEUTICS, INC. | $10.94B | $95.97 | — |
| PCVX | Vaxcyte, Inc. | $9.40B | $59.40 | — |
| TECH | BIO-TECHNE Corp | $11.41B | $72.63 | — |
News headlines (Yahoo Finance, 1h cache)
Repligen (RGEN) Stock Looks Fairly Valued As Cash Flow Growth Matters
2026-11-16 23:19 · Yahoo
What iShares Russell 2000 Index Fund (IWM) Bought: Jackson Leads on Nov. 5
2026-11-09 11:05 · Yahoo
Repligen: 3 Key Takeaways for Long-Term Investors
2026-11-05 16:50 · Yahoo
Repligen Corporation to Present at Jefferies Global Healthcare Conference
2026-11-04 12:00 · Yahoo
RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook
2026-11-01 02:19 · Yahoo
5 must-read analyst questions from Repligen’s Q3 earnings call
2026-10-31 14:35 · Yahoo
Repligen Announces $1 Billion Private Convertible Senior Notes Transaction
2026-10-30 10:00 · Yahoo
Repligen Corporation (RGEN) Surges on Revenue Beat and Raised Full-Year Organic Outlook
2026-10-28 15:09 · Yahoo
Repligen Corporation (RGEN) Benefits From Biotech Momentum and Strong Earnings
2026-10-28 14:14 · Yahoo
Repligen (RGEN) Could Be 12% Undervalued As Record Revenue Lifts Guidance
2026-10-28 01:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.